---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-129351"
form_type: "8-K"
ticker: "WW"
cik: "0000105319"
company_name: "WW INTERNATIONAL, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:49:14.612868+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# WW Q1 2024: Revenue $206.5M, op loss $269.3M on $258M impairment; subscriber flat 4.0M

## Summary
- Revenue $206.5M (-14.6% YoY); subscription revenue $204.1M (-3.3%); other revenue $2.5M (-92%).
- Operating loss $269.3M from $258M non-cash intangible impairment; adjusted operating loss $5.6M.
- Net loss $347.9M ($4.39 EPS) vs $118.7M ($1.68) prior year.
- End period subscribers 4.0M flat YoY; clinical subscribers 91K (from zero).
- FY2024 guidance: total subscribers 3.8-4.0M, clinical 140-160K; revenue guidance maintained.

## SEC filing metadata
- accession: 0001193125-24-129351
- form_type: 8-K
- ticker: WW
- cik: 0000105319
- company_name: WW INTERNATIONAL, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/0001193125-24-129351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/d787506d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-129351
- JSON: https://secwatch.observer/filing/0001193125-24-129351.json
- Plain text: https://secwatch.observer/filing/0001193125-24-129351.txt

## Key facts
- Earnings Releases
  WW INTERNATIONAL, INC. reported first quarter of fiscal 2024 results: revenue $206.5 million. Guidance reaffirmed.
  - Period: first quarter of fiscal 2024
  - Revenue: $206.5 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: WW International, Inc. Announces First Quarter 2024 Results • End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical Subscribers • Revenues of $206.5 million • Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross margin of 67.9% • Operating Loss of $269.3
  evidence_url: https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/0001193125-24-129351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.